Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CBMG, a China-US Biopharma, Starts China Trial of CAR-T Immunotherapy

publication date: Nov 30, 2016
Cellular Biomedicine Group of Shanghai and the Bay Area has begun a China Phase I clinical trial of its newly optimized CAR-T immunotherapy. C-CAR011 is a construct of the CD19 CAR-T therapy that CBMG in-licensed from Beijing's PLA General Hospital (the 301) last year. It will be tested as a treatment for patients with refractory Diffuse Large B-cell Lymphoma. CBMG is developing  immunotherapies for cancer and stem cell treatments for degenerative diseases. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here